These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2465401)

  • 1. Human immunodeficiency viruses: neutralization and receptors.
    Weiss RA; Clapham PR; McClure MO; McKeating JA; McKnight A; Dalgleish AG; Sattentau QJ; Weber JN
    J Acquir Immune Defic Syndr (1988); 1988; 1(6):536-41. PubMed ID: 2465401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.
    Zhang PF; Bouma P; Park EJ; Margolick JB; Robinson JE; Zolla-Pazner S; Flora MN; Quinnan GV
    J Virol; 2002 Jan; 76(2):644-55. PubMed ID: 11752155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of GP120 binding to CD4 and an assay that measures ability of sera to inhibit this binding.
    Schnittman SM; Lane HC; Roth J; Burrows A; Folks TM; Kehrl JH; Koenig S; Berman P; Fauci AS
    J Immunol; 1988 Dec; 141(12):4181-6. PubMed ID: 3264307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6.
    Verrier F; Nádas A; Gorny MK; Zolla-Pazner S
    J Virol; 2001 Oct; 75(19):9177-86. PubMed ID: 11533181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors.
    Dhillon AK; Donners H; Pantophlet R; Johnson WE; Decker JM; Shaw GM; Lee FH; Richman DD; Doms RW; Vanham G; Burton DR
    J Virol; 2007 Jun; 81(12):6548-62. PubMed ID: 17409160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120.
    Siliciano RF; Knall C; Lawton T; Berman P; Gregory T; Reinherz EL
    J Immunol; 1989 Mar; 142(5):1506-11. PubMed ID: 2537355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved and exposed epitopes on intact, native, primary human immunodeficiency virus type 1 virions of group M.
    Nyambi PN; Mbah HA; Burda S; Williams C; Gorny MK; Nádas A; Zolla-Pazner S
    J Virol; 2000 Aug; 74(15):7096-107. PubMed ID: 10888650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120.
    Sun NC; Ho DD; Sun CR; Liou RS; Gordon W; Fung MS; Li XL; Ting RC; Lee TH; Chang NT
    J Virol; 1989 Sep; 63(9):3579-85. PubMed ID: 2474670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of recombinant gp120 and gp160 from HIV-1: binding to monoclonal antibodies and soluble CD4.
    Moore JP; McKeating JA; Jones IM; Stephens PE; Clements G; Thomson S; Weiss RA
    AIDS; 1990 Apr; 4(4):307-15. PubMed ID: 2190605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The principal neutralization determinant of simian immunodeficiency virus differs from that of human immunodeficiency virus type 1.
    Javaherian K; Langlois AJ; Schmidt S; Kaufmann M; Cates N; Langedijk JP; Meloen RH; Desrosiers RC; Burns DP; Bolognesi DP
    Proc Natl Acad Sci U S A; 1992 Feb; 89(4):1418-22. PubMed ID: 1371358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and monocytes but not for brain and muscle cells.
    Clapham PR; Weber JN; Whitby D; McIntosh K; Dalgleish AG; Maddon PJ; Deen KC; Sweet RW; Weiss RA
    Nature; 1989 Jan; 337(6205):368-70. PubMed ID: 2536142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12.
    Zwick MB; Kelleher R; Jensen R; Labrijn AF; Wang M; Quinnan GV; Parren PW; Burton DR
    J Virol; 2003 Jun; 77(12):6965-78. PubMed ID: 12768015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD4 activation of HIV fusion.
    Sattentau QJ
    Int J Cell Cloning; 1992 Nov; 10(6):323-32. PubMed ID: 1281202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of HIV-1 primary isolates by polyclonal and monoclonal human antibodies.
    Hioe CE; Xu S; Chigurupati P; Burda S; Williams C; Gorny MK; Zolla-Pazner S
    Int Immunol; 1997 Sep; 9(9):1281-90. PubMed ID: 9310831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism between HIV gp120 and gp120-specific antibody in blocking human T cell activation.
    Mittler RS; Hoffmann MK
    Science; 1989 Sep; 245(4924):1380-2. PubMed ID: 2571187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen.
    Smith DH; Byrn RA; Marsters SA; Gregory T; Groopman JE; Capon DJ
    Science; 1987 Dec; 238(4834):1704-7. PubMed ID: 3500514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of sera from subjects infected with HIV-1 subtypes B and E in Thailand by antibody binding and neutralization.
    Louisirirotchanakul S; Beddows S; Cheingsong-Popov R; Shaffer N; Mastro TD; Auewarakul P; Likanonsakul S; Wasi C; Weber J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Dec; 19(4):315-20. PubMed ID: 9833739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.